TOPIGEN

April 03, 2006 08:13 ET

Dr. Mitchell Glass Joins TOPIGEN's Scientific Advisory Board

MONTREAL and PARSIPPANY, NJ--(CCNMatthews - April 2, 2006) - TOPIGEN Pharmaceuticals, Inc., a biopharmaceutical company specializing in innovative respiratory therapeutics, today announced the appointment of Dr. Mitchell Glass to its Scientific Advisory Board (SAB). Dr. Glass is a pulmonary and critical care specialist and recognized expert in developing drug products for pulmonary and inflammatory-related disorders.

"We welcome Dr. Glass to TOPIGEN's SAB," said Dr. Paolo Renzi, TOPIGEN's Founder and Chief Scientific Officer. "Dr. Glass brings extensive drug development experience and regulatory expertise to our already world-class advisory board at an important time in our progression, as we move from drug discovery into clinical development with two Phase II compounds in the clinic for asthma and COPD."

Dr. Glass' distinguished career is highlighted by his leadership in directing numerous Investigational New Drug Applications and product approvals through the FDA, including ACCOLATEr (zafirlukast) marketed by AstraZeneca, the first leukotriene receptor antagonist to receive FDA clearance for the asthma.

"TOPIGEN is pursuing excellent science and products with the potential to address major pulmonary care medical needs," said Dr. Glass. "I admire Dr. Renzi's pioneering work in the area and I am delighted to be joining the other members of the SAB to advance TOPIGEN's research and products in the field."

Dr. Glass is presently Senior Vice President and Chief Scientific Officer of the Science Center, a Philadelphia-based life-science "Venture Ecosystem" that forms and funds early-stage companies. Prior to joining the Science Center, he held various senior positions with both emerging biotech and large pharmaceutical companies; including COO of geneRX, a gene-therapy start-up focused on emphysema; and Chief Medical Officer at AtheroGenics focused on inflammatory atherosclerosis.

Dr. Glass also served as Vice President of the CardioPulmonary Therapeutic Unit at SmithKline Beecham, where he was responsible for developing a broad portfolio of drugs for the treatment of respiratory, cardiovascular, metabolic and renal diseases. He was also the Senior Director of Pulmonary Therapeutics at Zeneca Pharmaceuticals, where he directed the successful drug development of ACCOLATEr. Dr. Glass received his medical degree from the University of Chicago and is a member of the American Thoracic Society and American Academy of Asthma, Allergy & Immunology.

TOPIGEN's SAB is comprised of nine distinguished scientists, and plays an important role in guiding TOPIGEN's research and clinical development programs. In addition to Drs. Renzi and Glass, the SAB consists of: Drs. Douglas Kornbrust (SAB Chairman) Preclinsight, Paul O'Byrne, McMaster University, Mark Fitzgerald, Vancouver Hospital, R.P. (Kris) Iyer, Spring Bank Technologies, Alan Gewirtz, University of Pennsylvania School of Medicine, Masad J. Damha, McGill University and Gordon Schooley, SkyePharma.

About TOPIGEN

TOPIGEN is a privately-held biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. TOPIGEN's pipeline includes small molecule and RNA-based therapeutics. The Company's Phase II products and research programs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This pioneering approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis. For more detailed information on TOPIGEN visit www.topigen.com.


Contact Information